Multi-Omics Study Reveals Nc886/vtRNA2-1 as a Positive Regulator of Prostate Cancer Cell Immunity.

Area of Science:

• Molecular Biology
• Immunology
• Oncology

Background:

• Noncoding RNA 886 (nc886) is a regulatory RNA with known tumor suppressor functions in prostate cancer.
• The precise molecular mechanisms by which nc886 exerts its effects in prostate cancer remain largely unknown.

Purpose of the Study:

• To elucidate the key molecular pathways regulated by nc886 in prostate cancer.
• To investigate the role of nc886 in immune system modulation within prostate cancer models.

Main Methods:

• Transcriptomic and proteomic analyses were performed on prostate cancer cell lines (DU145, LNCaP, PC3) and a benign cell line (RWPE-1).
• Cells were manipulated with nc886 or antisense oligonucleotides to assess gain and loss of function.
• Gene Set Enrichment Analysis (GSEA) was conducted on The Cancer Genome Atlas (TCGA) Prostate Cancer (PRAD) dataset.

Main Results:

• Multiomics analysis revealed significant enrichment of immune system pathways, including cytokine and interferon signaling, upon nc886 modulation.
• Functional assays confirmed nc886 provokes an interferon response, operating through a PKR-independent mechanism.
• GSEA of clinical data identified immune stimulation as the most significantly associated pathway with nc886 levels in prostate cancer.

Conclusions:

• nc886 plays a crucial role in regulating immune responses within the prostate cancer microenvironment.
• The findings suggest nc886 enhances innate immunity in prostate cancer via a PKR-independent pathway.
• Reduced nc886 levels are associated with a diminished immune response in prostate cancer, offering potential therapeutic insights.